Effects of semaglutide on blood glucose,serum adipokines and visceral fat parameters in obesity patients with T2DM
Objective To explore the effects of semaglutide on blood glucose fluctuation,serum adipokines and visceral fat parameters in obesity patients with type 2 diabetes mellitus(T2DM).Methods A total of 106 obesity patients with T2DM treated in the hospital were retrospectively analyzed between June 2022 and January 2024.According to propensity matching method,they were divided into a combination group(metformin+semaglutide)and a metformin group(metformin),53 cases in each group.All patients were treated for 2 months.The curative effect in the two groups was compared.Results After treatment,total response rate of combination group was higher than that of metformin group(94.3％vs 79.3％,P＜0.05).The mean amplitude of glycemic excur-sion(MAGE),visfatin and visceral adiposity index(VAI)in combination group were lower than those in metformin group,while adipsin was higher than that in metformin group[(3.37±0.51)mmol/L vs(3.83±0.56)mmol/L,(65.35±6.28)μg/L vs(71.58±6.88)μg/L,(80.06±7.71)μg/L vs(85.19±8.12)μg/L,(5 013.55±413.61)ng/ml vs(4761.36±408.79)ng/ml,P＜0.05].After treatment,there was no difference in adverse reactions between the two groups(P＞0.05).Conclusion Semaglutide can control blood glucose fluctuation,regulate serum adipokines and improve visceral fat parameters in obesity patients with T2DM,which has high safety and effectiveness.
NETL
NSTL
万方数据
